Interim Report 2026
Filed with HKEX · Stock code 1873 · · 93 pages · English
Earlier from Viva Biotech
- Viva Biotech Announces Its 2026 Interim Results: AI Sparks New Paradigm in Drug R&D, CDMO Commercial Manufacturing Accelerates Revenue Growth
- Viva Biotech Announces 2025 Annual Results: AI-Driven Drug Discovery Reinforces Industry Leadership, CDMO Commercial Products Enter Rapid Scale-Up
- Adventures in DMPK: Viva Biotech's One-Stop Pharmacology Platform Cross New Modalities
- Viva Biotech's invested and incubated company, Arthrosi, has entered into an acquisition agreement with Sobi for a total transaction value of up to US$1.5 billion.
- Viva Biotech Receives Frost & Sullivan's 2025 APAC Technology Innovation Leadership Recognition in the Integrated Intelligent Drug Discovery Industry
Later from Viva Biotech
All Viva Biotech news releasesFollow Viva Biotech into a list and get an email when it puts out news.
Follow Viva Biotech